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1 Introduction
The role of idiopathic respiratory distress syn-
drome (IRDS) in perinatal death is proved by
data published in various countries [7, 9, 10,
24, 26, 27]. In view of the high incidence of
premature births in Hungary as well as observa-
tions that it is premature birth above all which
predisposes the development of IRDS, steroid
prophylaxis remains in the center of profession-
al interest [14,16, 22, 26, 27], As numerous side
effects and risks for steroid administration is
known [10, 18], other possibilities should be
investigated for preventive medication. Wu et
al. [29, 30] with laboratory animal experiments,
MACHIACH et al. [11, 12, 21] in human subjects
proved that other pharmacologic agents can be
used. Intraamniotically administered thyroxin
beneficially influences the development of pul-
monary surfactant, and it is applicable for pre-
venting IRDS. Since 1974 we have regularly
used dexamethasone for IRDS prophylaxis;
thus, we have had the opportunity to observe
that in pregnancy complicated by toxemia, in-
trauterine death was more frequent following
steroid prophylaxis. It seemed reasonable that
for IRDS prophylaxis, thyroxin should be ad-
ministered intraamniotically in pregnancy com-
plicated by preeclamptic toxemia. Our purpose
is to report our observations on the effects of
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intraamniotically applied L-Thyroxin "Hen-
ning".
2 Material and method
Between January 1, 1982 and January 1, 1984
according to WITTLINGER, 18 cases of serious
and fairly serious toxemic pregnancy were ad-
ministered 500 g of L-Thyroxin "Henning" in
a single dose intraamniotically after the labora-
tory findings of negative pulmonary maturity
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in the amniotic fluid. The ages of the patients
were between 16 and 39 years with a gestational
age of 29—40 weeks (mean: 36.3 weeks). Prior
to the considered therapy but after the
thorough clinical examinations of the mother,
amniotic fluid was obtained by ultrasound-di-
rected transabdominal amniocentesis with a
PICKER LS 2700 ultrasound machine. After
obtaining 30ml of amniotic fluid, the needle
was left in place with sterile closing. For rapid
determination, a Clements test was performed,
and in case it showed pulmonary immaturity,
via the same needle, 500 μg of L-Thyroxin
"Henning" was injected into the amnionic fluid.
Removing the needle, the patient was kept
under surveillance for 24 hours. Prior to thyrox-
in treatment, cholesterin test was made from
cubital vein and the level of estriol, HPL, as
well as Ts and T4 were determined by Ria
method. The same parameters were examined
1 hour after thyroxin administration as well as
every 24 hour interval up to parturition. After
delivery, the same parameters were determined
as well as the level of Ts and T4 from mixed
blood from the umbilical cord. Besides the
Clements test, as part of amniotic fluid analysis,
the L/S ratio, amniocrit, glucose, creatinine,
estriol and HPL values were determined. In
every case the bacteriological examination of
the amniotic fluid was performed. Forty-eight
hours after medication the amniocentesis was
repeated and the chosen parameters rechecked.
When medically indicated, labor was induced.
When the maternal/fetal state did not require
induction, we awaited the onset of spontaneous
labor while performing intrauterine examina-
tions. After delivery Ts and T4 levels were deter-
mined from mixed cord blood.
During the postnatal period, the neonatologist
kept the newborn under strict surveillance to
observe any early possible side effects. In the
5th day after delivery, from venous blood, the
Ts and T4 levels were repeated by Ria method.
It was not possible to measure Ts levels from
amniotic fluid because a precipitate was not
obtainable from the tube.
The changes of the T4 level and the L/S ratio
in the amniotic fluid as well as that of T4 in the
cord were statistically analyzed by Student's x2-
test.
3 Results
The effect of the intraamniotically administered
thyroxin on the various parameters examined
is presented in table I. 48 hours after thyroxin
administration, the T4 level of the amniotic
fluid showed an increase of extreme degree; the
difference was very significant (p < 0.001). The
maternal Ts and T4 levels did not change due
to the medication (figure 1).
When the delivery occured 48 hours after medi-
cation, the T4 level gradually decreased in the
amniotic fluid, and 5 — 6 days after thyroxin
administration the T4 levels practically showed
the prior value. Forty-eight hours after thyrox-
in administration the L/S ratio rose more then
two times in each case (figure 2).
The T4 level in the cord blood taken after deliv-
ery, increased compared to the basic value but
the difference was not significant (p > 0.05).
Table I. Effect of intraamniotically given L-Thyroxin
"Henning" (500 μ§) on the examined parameters.
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*T3 non-measurable in amniotic fluid
Figure 1. Level of Ts and T4 in maternal serum and
amniotic fluid after 24—48 hours intraamniotically gi-










48 hours a f t e r
administration of Thyroxin
Figure 2. Effect of intraamniotically given thyroxin on
L/S ratio.
This may be explained by the fact that the
majority of deliveries occured several days after
medication. The level of newborn venous blood
was also normal in the 5th postnatal day show-
ing euthyreoid values. During neonatal intensi-
ve surveillance, no change was observed that
could have been due to thyroxin effect.
In the period of investigation, 1584 deliveries
were performed, 58 of which were serious and
fairly serious toxemic pregnancies as defined by
WITTLINGER. Thyroxin was not given in 40 cases
for the following reasons: contraindication, pre-
mature rupture of membrane, fetal distress, in-
trauterine death and also when the test of amni-
otic fluid demonstrated fetal pulmonary matur-
ity. These 40 cases were regarded as the non-
treated group. The data obtained from the thy-
roxin treated group and the non-treated group
are presented in table II.
Table II. Important data of the thyroxin treated group
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Although 7 of the 18 thyroxin treated pregnant
women were delivered of premature infants,
IRDS of HMB was not observed. Among the
premature infants of the 40 toxemic pregnant
women, who were not treated with thyroxin,
IRDS was observed in 8 cases, and 2 of the
infants were under 1500g and died. In both
cases the autopsy findings demonstrated hya-
line membrane disease (in one of the two the
direct cause being intracranial hemorrhage). In
this thyroxin-non-treated group 5 additional
infants were lost.
,.,. . . . . . , ., . . . ,.Five mtrauterme deaths prior to delivery were
due to toxemic placenta] msufficiency accord-
\mg to the autopsy findings.a r * &
The details of one of the fetal loss in the thyr-
oxin-treated group are the following:
The gravida was in the 33rd gestational week was hospi-
talized with the diagnosis of preeclamptic toxemia. The
delivery was induced because her blood pressure was
180-190/130 torr despite medication. Her proteiunuria
was rapidly progressing (to 28.7 g/day) in the collected
urine, and in addition the estriol level was too low for
measurement. An amniocentesis was performed before
the induction and indicated pulmonary immaturity
(Clements test: negative, L/S ratio: 1.2, amniocrit: 0.20,
S «βΑΪΑΑ ES
after the medication, her temperature rose and intrauter-
ine death occurred. The fetus weighed 2100 g, and the
autopsy could demonstrate only symptoms of intrauter-
lar weight (TBG) cannot pass through the
placental barrier. The level of maternal T4 can
influence that of the fetal's only in early preg-
nancy (under 18 weeks). He also proved that
the T4 reaches the fetus via the amniotic fluid.
The T4 level of the amniotic fluid can be meas-
ured and its changes follow those from the fetal
serum level. It was also established that in the
fetus, the thyroid hormones favorably influence
the growth of the bone structure, the develop-
ment of the nervous system, the myeliriization
and increase the production of pulmonary sur-
factant in the II type pneumocytes [1, 5, 6, 8,
KniXwA et al. [29, 30] proved
^ intraamnioticallv administered thyroxin. , Λ * . f . . , ι · t uincreased the pulmonary surfactant level m lab-
oratory animals. The action of mechanism pre-
sumably takes effect by accelerating the dif-
ferentiation of a certain enzymetic system. Ob-
servations on patients are not unanimous. In-
traamniotically administered T4 is used not only
for JRDS prevention but also for other tfiera-
. ΎΤ7 * \ r-0, ^ , ^ ^Pies- WEINER et al. [28] attempted to treat pro-
ved fetal goiter in the 30th gestational week by
intraamniotically applied T4. SCHREIER et al.
no] could not observe a decressed incidence of
»Ι« «ft« intraaomiotically administered T,.
MACHIACH et al. [11, 12] reported Significantly
decreasing incidence of IRDS following in-
traamniotically administered T4. DUDENHAUSEN
4 Discussion
administration the lecithin level m the amniotic
fluid significantly increased and, parallel with
^s' ̂ e °^servec^ number of hyaline membrane
syndrome decreased. However, in the 22 cases
The dangers of preeclamptic toxemia both for examined, on five occasions fetal tachycardia
the mother and the fetus are well known [2, 4, could be observed 2 days after the thyroxin
18, 23]. One of the most effective means of administration. In 1982 we reported [13, 25]
preventing complications is an induced preterm favorable results obtained in a few cases; thus
delivery. The greatest danger of a poorly timed the drug has been used in a larger number of
preterm delivery is IRDS, due to pulmonary cases. On the basis of our results it is concluded
immaturity. In cases of serious toxemia, after that thyroxin, in the applied dose, brings about
steroid administration, the number of intrauter- within 48 hours, an increase in the L/S ratio as
ine deaths rise [2, 10, 18]. In recent years more well as the Clements test used for determina-
authors reported that thyroxin stimulated the tions of pulmonary surfactant. The other para-
surfactant production. The role of Ts and T4 meters examined in the amniotic fluid, rep-
in fetal development has not been cleared up resenting functional and somatic maturity, and
including the physiology. NIVELON [15] pointed the hormone estriol, HPL levels indicating the
out that T4 bound to a protein of great molecu- intrauterine state of the fetus, did not change
J. Perinat. Med. 14 (1986)
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due to thyroxin. Neither in the mother nor in
the newborn was clinical side effect observed
due to thyroxin prophylaxis. The T4 was rapidly
eliminated from the amniotic fluid. The post-
medication T4 level in the fetus was gradually
decreased depending on the time that elapsed
until delivery, and on the 5th to 6th days follow-
ing the thyroxin administration it was almost
normal. On the post-natal 5th day, the T4 levels
of the venous blood taken from the newborn
infants did not show any increase. The passage
of the drug via amniotic fluid to the fetus pre-
sumably stops at the placenta barrier and the
thyroxin does not reach the mother. This pre-
sumption is supported by the fact that an in-
creased thyroxin level was not observed in the
maternal venous blood regardless of the time
of administration. The placenta serves as a two-
way barrier (mother-fetus, fetus-mother) for the
drug. This is supported by our observation that
following the intraamniotically administered
500 g L-Thyroxin, the maternal levels were
not altered. In our opinion, in cases of serious
and fairly serious preeclamptic toxemia, where
the induction of labor is vital, in the interest
of the fetus, intraamniotically administered L-
Thyroxin can be effectively applied, though a
premature birth can be inevitable.
Summary
In 18 cases of serious and fairly serious toxemic pregnan-
cy, the authors gave 500 § L-Thyroxin "Henning" in-
traamniotically after the laboratory evaluation demon-
strated negative pulmonary maturity from an amniotic
fluid sample. Maternal and fetal complications due to
the drug could not be observed. Despite a 39% prematu-
re incidence, IRDS and hyaline membrane disease were
not observed. The administered T4 caused a positive
change in the direction of the L/S ratio and the Clements
test. The other amniotic fluid parameters did not change,
exept the T4 level. The extremly high T4 level obtained
48 hours later gradually became normal several days
later. The T4 values obtained from the blood of the
mother and the newborn on the 5th postnatal day were
normal. In toxemic cases where the induction of labor
is vital and there is a risk of IRDS and steroid applica-
tion in contraindicated, intraamniotic thyroxin is recom-
mended as prophylaxsis for IRDS.
Keywords: Fetal pulmonary maturity, preeclamptic toxemia, thyroxin.
Zusammenfassung
*
Wirkung einer intraamnialen Thyroxingabe auf die Akze-
leration der fetalen Lungenreife bei Präeklampsie
Bei 18 Schwangeren mit schwerer bzw. mäßiger präe-
klamptischer Symptomatik wurden 500 g L-Thyroxin
„Henning" intraamnial appliziert. Zuvor hatte die labor-
chemische Untersuchung des Fruchtwassers eine fehlen-
de Lungenreife ergeben. Wir konnten weder bei der
Mutter noch beim Feten Komplikationen als Folge der
Medikation beobachten. Trotz einer Frühgeburtsinzi-
denz von 39% trat in keinem Fall ein RDS auf. Das
applizierte T4 veränderte die L/S-Ratio im Fruchtwasser
Mots-cles: Fetale Lungenreife, Präeklampsie, Thyroxin.
und das Ergebnis des Clements-Tests in positiver Rich-
tung. Andere Parameter im Fruchtwasser veränderten
sich mit Ausnahme des T4-Spiegels nicht. Der extrem
hohe T4-Spiegel nach 48 Stunden normalisierte sich
schrittweise einige Tage später. Die T4-Blutspiegel lagen
am 5. Tag post partum bei Mutter und Kind im Normbe-
reich. Ist eine Geburtseinleitung bei Präeklampsie vital
indiziert und liegt das Risiko für ein RDS vor, so wird
bei Vorliegen einer Kontraindikation für Steroide die
Prophylaxe eines RDS mittels intraamnialer Thyroxin-
gabe empfohlen.
Resume
Les effets de la thyroxine en injection intra-amniotique
sur l'acceleration de la maturite pulmonaire fetale dans
le preeclampsie
Les auteurs ont administre en intra-amniotique 500 g
de L. thyroxin «enning» au cours de 18 grossesses avec
toxemie grave ou assez grave apres que le laboratoire
ait montre une immaturite pulmonaire sur l'analyse du
liquide amniotique. II n'a pas ete observe de complica-
tions maternelles ou totales secondaires au medicament.
H n'a pas ete observe non plus de SDR ou de maladie
J. Perinat. Med. 14 (1986)
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des membranes hyalines malgre une incidence de prema-
turite de 39%. La T4 administree a positive le rapport
L/S du liquide amniotique ainsi que le test de Clement.
Les autres parametres du liquide amniotique ne sont pas
modifies a Pexception du taux de T4. Le taux tres eleve
de T4 obtenu ä 48 heures se normalise ensuite progressi-
vement en quelques jours. Les valeurs de T4 chez la mere
et chez le nouveau-ne etaient normales au cinquieme
jour du post-pärtum. Dans les cas de toxemie ou 1'induc-
tion du travail est vitale et oü il y a un risque de
SDR avec contre-indication. aux cortico'ides, les auteurs
recommandent Pinjection intra-amniotique de thyroxine
comme prophylaxie de SDR.
Mots-cles: Maturite pulmonaire foetale, preeclampsie, thyroxine.
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Despite more than a century of ever-increasing scientific interest and research,
anorexia nervosa - the pathological pursuit of thinness - still presents a chal-
lenge to clinicians throughout the world. It has become practically impossible to
keep in touch with the constant proliferation of scientific literature on this sub-
ject. Moreover, the clinician (the general practitioner, the psychiatrist or the psy-
chologist) needs, first and foremost, practical guidelines for his everyday thera-
peutic work with these patients.
Therefore, two experienced clinicians, who are daily involved in research and
treatment of large numbers of anorexia nervosa patients, decided to write the
first book dealing extensively with the many practical issues one is faced with
when investigating and treating anorectic patients of all ages and in all stages of
their illness. No single treatment modality, psychotherapeutic, pharmacologic or
nutritional, has provided the final solution for the management of this intriguing
syndrome. Hence, the therapeutic approach described in this book Is characte-
rized as an eclectic, broad spectrufti or multimodal treatment in which strate-
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